Acumen Pharmaceuticals (ABOS) AI Stock Analysis

• Market Cap: $59.49M
• Dividend Yield: N/A
• Average Volume (3M): 243.55K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.36
• Revenue Growth: N/A
• EPS Growth: -57.45%
• Country: US
• Employees: 61
• Sector: Healthcare
• Sector Strength: 64
• Industry: Biotechnology
• EPS (TTM): -1.70
• Shares Outstanding: 60,573,425
• 10 Day Avg. Volume: 258,835
• 30 Day Avg. Volume: 243,546
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 14419.15
• Price to Cash Flow (P/CF): -0.70
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $9.00
• Price Target Upside: 818.37% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

Acumen Pharmaceuticals faces considerable financial challenges with no revenue and increasing losses. Technical analysis shows bearish momentum, and the low valuation reflects the company's current unprofitability. However, progress in clinical trials and a solid cash position provide some positive outlook.

Positive Factors

Clinical Trials

Completion of enrollment of ALTITUDE AD indicates an overall enthusiasm for a differentiated anti Abeta immunotherapy despite the availability of two drugs in the market.

Financial Stability

ABOS finished with $231.5M in cash and cash equivalents, sufficient to fund operations into 1H27.

Screening Process

Acumen's use of ptau217 screening assays in the ALTITUDE-AD trial has effectively enrolled and enriched amyloid-positive patients, reducing negative screening by nearly 50%.

Negative Factors

Price Target Adjustment

The reevaluation of operational expense assumptions has led to a reduction in the price target from $15 to $11.

Safety Concerns

The subQ formulation of sabirnetug, although showing a decent safety profile, has a very high proportion of mild injection site reactions at around 62.5%.

Acumen Pharmaceuticals Business Overview & Revenue Model

Company Description

Acumen Pharmaceuticals, Inc. (ABOS) is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for the treatment of neurodegenerative diseases, with an emphasis on Alzheimer's disease. The company's lead product candidate is ACU193, a monoclonal antibody that selectively targets toxic amyloid-beta oligomers, which are believed to play a key role in the pathogenesis of Alzheimer's disease. Acumen Pharmaceuticals is engaged in advancing its clinical trials and research to address unmet medical needs in the neurodegenerative disease sector.

How the Company Makes Money

Acumen Pharmaceuticals generates revenue primarily through funding from investors, partnerships, and collaborations rather than traditional product sales, as it is still in the clinical trial phase. The company relies on strategic alliances with pharmaceutical companies, research institutions, and government grants to support its research and development activities. Additionally, Acumen may receive milestone payments and royalties from potential future licensing agreements for its drug candidates, contingent upon successful clinical development and regulatory approval.

Acumen Pharmaceuticals Financial Statement Overview

Summary

Acumen Pharmaceuticals faces significant financial challenges with no revenue generation and mounting losses. The balance sheet is stable with no debt, but declining assets could pose future liquidity risks. Cash flow issues are prominent, with heavy reliance on financing activities to support operations.

Income Statement

Acumen Pharmaceuticals' income statement shows a persistent lack of revenue generation, with total revenues standing at zero for the past four years. The company has been experiencing substantial net losses, with a notable increase in net loss from $73.2 million in 2020 to $102.3 million in 2024. The absence of revenue combined with increasing operating losses highlights significant challenges in achieving profitability.

Balance Sheet

The balance sheet reflects a stable equity base, with stockholders' equity exceeding liabilities, indicating a low risk of insolvency. However, the company has seen a decline in total assets from $310.1 million in 2023 to $239 million in 2024. The absence of debt provides financial flexibility, but the consistent decrease in asset base may indicate potential liquidity concerns.

Cash Flow

The cash flow statement reveals negative free cash flow over the years, with an increasing deficit from $43 million in 2023 to $86 million in 2024. Operating cash flow remains negative, highlighting ongoing challenges in generating cash from operations. Financing activities have been a critical source of cash, but reliance on external financing may not be sustainable long-term.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
290.00K	0.00	0.00	0.00	0.00	1.44M
	Gross Profit
162.00K	0.00	-42.32M	-169.00K	-4.00K	1.43M
	EBIT
-92.91M	-114.02M	-61.14M	-45.24M	61.57M	-7.91M
	EBITDA
-75.48M	-114.02M	-51.61M	-42.69M	61.58M	587.00K
	Net Income Common Stockholders
-81.67M	-102.33M	-52.37M	-40.48M	-181.68M	-7.32M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
6.55M	171.56M	243.52M	177.60M	194.24M	43.78M
	Total Assets
0.00	238.99M	310.13M	196.59M	230.33M	44.43M
	Total Debt
0.00	0.00	28.49M	105.00K	0.00	0.00
	Net Debt
6.55M	-35.63M	-38.40M	-130.00M	-122.16M	-43.78M
	Total Liabilities
0.00	57.18M	43.15M	7.81M	5.15M	63.02M
	Stockholders Equity
5.98M	181.82M	266.97M	188.78M	225.18M	-18.59M
Cash Flow		Free Cash Flow
-67.34M	-86.23M	-43.09M	-35.31M	-18.00M	-7.45M
	Operating Cash Flow
-67.31M	-86.22M	-43.06M	-35.15M	-17.96M	-7.45M
	Investing Cash Flow
-30.44M	48.03M	-171.67M	39.19M	-104.12M	0.00
	Financing Cash Flow
36.07M	6.93M	151.75M	3.91M	200.47M	44.67M

Acumen Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.98
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABOS, the sentiment is Negative. The current price of 0.98 is below the 20-day moving average (MA) of 1.06, below the 50-day MA of 1.20, and below the 200-day MA of 2.11, indicating a bearish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 42.35 is Neutral, neither overbought nor oversold. The STOCH value of 38.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ABOS.

Acumen Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$5.20B	3.18	-40.80%	2.96%	17.66%	1.94%
IVVD	44 Neutral	$73.88M	―	-138.71%	―	―	20.91%
ABOS	43 Neutral	$59.49M	―	-45.60%	―	―	-57.45%
ASMB	34 Underperform	$75.56M	―	-107.92%	―	298.16%	50.72%
RANI	32 Underperform	$62.66M	―	-404.07%	―	―	20.85%

Acumen Pharmaceuticals Corporate Events

Acumen Pharmaceuticals Completes Enrollment for Phase 2 Study

On March 27, 2025, Acumen Pharmaceuticals announced the completion of enrollment for its ALTITUDE-AD Phase 2 study, investigating sabirnetug for early Alzheimer’s disease, with topline results expected in late 2026. The company reported a cash balance of $231.5 million as of December 31, 2024, projected to support operations into the first half of 2027, despite a net loss of $102.3 million for 2024 due to increased R&D expenses.